NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Initiates Program to Treat Patients with Pulmonary Complications from COVID-19 Infection with TNF Inhibitor “DN-TNF” Platform
INmune Bio (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, on Monday announced the initiation of a therapeutic program to treat patients with pulmonary complications from COVID-19 infection with its dominant-negative TNF inhibitor (“DN-TNF”) platform. According to the update, the program targets patients admitted to the hospital with hypoxia who do not yet require intensive respiratory support. If successful, DN-TNF treatment should decrease the need to transfer patients to the ICU and the need for mechanical ventilation. “In response to reports highlighting the role of TNF in the cytokine storm of…







